InMode has reported preliminary Q2 2026 revenue guidance of $95.2M–$95.4M, exceeding analyst expectations and reiterating full-year 2026 revenue guidance of $365M–$375M. The beat occurs against the backdrop of the unsolicited Steel Partners takeover bid, suggesting underlying demand strength for the company's monopolar RF and fractional ablative platforms.
Business & M&A
InMode Guides Q2 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Target
Device maker's preliminary results beat expectations amid takeover contest.
InMode's Q2 beat and $365M–$375M FY guidance underscore strong RF demand, even as takeover contest unfolds.
The revenue trajectory reflects sustained adoption of Morpheus8 and related systems across independent medspas, dermatology practices, and plastic surgery centers. For practice owners, the key takeaway is InMode's market momentum—and the uncertainty a contested acquisition introduces. Equipment pricing, rebate structures, and financing terms could shift materially depending on which bidder prevails. The company reports full results August 5.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.